In a retrospective real-world observational study conducted by the European Research Initiative on CLL (ERIC), the mutations in BTK and/or PLCG2 were not present in 35% of patients at the time of progression [29]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.